封面
市場調查報告書
商品編碼
1741263

支氣管擴張藥物市場按藥物類別、給藥途徑、分銷管道和地區分類

Bronchiectasis Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

支氣管擴張藥物市場規模預計在 2025 年為 4.069 億美元,預計到 2032 年將達到 8.031 億美元,2025 年至 2032 年的年複合成長率(CAGR)為 10.2%。

報告範圍 報告詳細資訊
基準年 2024 2025年的市場規模 4.069億美元
效能數據 2020-2024 預測期 2025-2032
預測期:2025-2032年複合年成長率: 10.20% 2032年價值預測 8.031億美元

支氣管擴張症是一種肺部管道(氣道)因損傷而擴張或形成囊狀的疾病。支氣管擴張症使肺部黏液難以排放,導致頻繁感染疾病。支氣管擴張症的主要症狀是咳嗽,伴隨膿液或黏液。支氣管擴張症無法治愈,但可以透過治療進行控制。

支氣管擴張症是一種以氣道擴張為特徵的慢性呼吸系統疾病,治療支氣管擴張症的藥物對於控制其症狀和併發症至關重要。這些藥物旨在緩解慢性咳嗽、過多黏液分泌和反覆呼吸道感染疾病等症狀,同時減緩病情進展。治療支氣管擴張症的藥物包括支氣管擴張劑、黏液清除劑、抗生素和抗發炎藥物。這些進展為改善患者預後和生活品質開闢了新的可能性。正在進行的支氣管擴張症研究正在探索新的治療方法和標靶藥物,這為更有效的治療和更好的疾病管理帶來了希望。

市場動態:

預測期內,支氣管擴張症盛行率的上升、治療方案的進步以及對個人化醫療的日益關注預計將推動全球支氣管擴張症藥物市場的成長。此外,有利的法規環境和市場參與者研發活動的活性化預計將推動市場在預測期內的成長。

例如,2022年2月,生物技術公司Armata Pharmaceuticals, Inc.宣布,美國食品藥物管理局(FDA)已核准Armata的臨床實驗(IND)申請,以啟動其最佳化的領先治療候選藥物AP-PA02的臨床試驗,用於治療第二種適應症-非囊腫纖維化支氣管擴張。

本研究的主要特點

  • 本報告對全球支氣管擴張藥物市場進行了詳細分析,並提供了預測期 2025-2032 的市場規模和年複合成長率(CAGR),以 2024 年為基準年。
  • 它還強調了各個領域的潛在商機,並說明了該市場的有吸引力的投資提案矩陣。
  • 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
  • 它根據公司亮點、產品系列、關鍵亮點、業績和策略等參數,介紹了全球支氣管擴張藥物市場的主要企業概況。
  • 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
  • 全球支氣管擴張藥物市場報告涉及該行業的各個相關人員,例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
  • 相關人員可以透過用於分析全球支氣管擴張治療市場的各種策略矩陣來促進他們的決策。

目錄

第1章 調查目的與前提條件

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告描述
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map(COM)

第3章市場動態、法規與趨勢分析

  • 市場動態
    • 驅動程式
  • 支氣管擴張盛行率不斷上升
  • 意識提升
    • 限制因素
  • 缺乏認知和診斷不足
  • 缺乏具體的治療指南
    • 機會
  • 未滿足的醫療需求
  • 新興市場
  • 影響分析
  • 主要亮點
  • 監管情景
  • 產品發布/核准
  • PEST分析
  • 波特分析
  • 併購場景

第4章。支氣管擴張藥物市場-冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19流行病學
  • 供需側分析
  • 經濟影響

5. 2020 年至 2032 年支氣管擴張藥物市場(依藥物類別分類)

  • 抗生素
  • 黏液溶解劑
  • 支氣管擴張劑
  • 抗發炎劑

6. 支氣管擴張藥物市場(依給藥途徑),2020 年至 2032 年

  • 口服
  • 吸入
  • 靜脈

7. 支氣管擴張藥物市場(依分銷管道分類),2020 年至 2032 年

  • 醫院藥房
  • 零售藥局
  • 網路藥局

8. 支氣管擴張藥物市場(按地區分類),2020 年至 2032 年

  • 北美洲
      • 美國
      • 加拿大
  • 歐洲
      • 英國
      • 德國
      • 法國
      • 義大利
      • 西班牙
      • 俄羅斯
      • 其他歐洲國家
  • 亞太地區
      • 中國
      • 日本
      • 印度
      • 韓國
      • ASEAN
      • 澳洲
      • 其他中東地區
  • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
      • 其他拉丁美洲
  • 中東
      • GCC
      • 以色列
      • 其他中東地區
  • 非洲
      • 南非
      • 北非
      • 中部非洲

第9章 競爭態勢

  • Bayer
  • GlaxoSmithKline
  • Boehringer Ingelheim
  • Novartis
  • AstraZeneca
  • Sunovion Pharmaceuticals
  • Chiesi Farmaceutici

第 10 章 章節

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI6011

Bronchiectasis Drugs Market is estimated to be valued at USD 406.9 Mn in 2025 and is expected to reach USD 803.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.2% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 406.9 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 10.20% 2032 Value Projection: USD 803.1 Mn

Bronchiectasis is a condition where damage causes the tubes in your lungs (airways) to widen or develop pouches. It makes it hard to clear mucus out of your lungs and can cause frequent infections. Coughing a lot with pus and mucus is the main symptom of bronchiectasis. Bronchiectasis can't be cured but can be managed with treatment.

Bronchiectasis drugs are essential for managing the symptoms and complications of bronchiectasis, a chronic respiratory condition characterized by widening of the bronchial tubes. These drugs aim to alleviate symptoms like chronic cough, excessive mucus production, and recurrent respiratory infections while slowing down disease progression. Bronchiectasis drugs encompass bronchodilators, mucus-clearing agents, antibiotics, and anti-inflammatory medicine. Their development has opened new possibilities for improved patient outcomes and quality of life. Ongoing research in bronchiectasis explores novel therapeutic approaches and targeted medications, offering hope for more effective treatments and better disease management.

Market Dynamics:

The increasing prevalence of bronchiectasis, advancements in treatment options, and increasing focus on personalized medicine are anticipated to drive growth of the global bronchiectasis drugs market over the forecast period. Moreover, a supportive regulatory environment and increased research and developmental activities by market players is expected to drive market growth over the forecast period.

For instance, in February 2022, Armata Pharmaceuticals, Inc., a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared Armata's Investigational New Drug (IND) application to initiate a clinical trial of its optimized lead therapeutic candidate, AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis.

Key features of the study:

  • This report provides in-depth analysis of the global bronchiectasis drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bronchiectasis drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Bayer AG, GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, Sunovion Pharmaceuticals, Chiesi Farmaceutici
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global bronchiectasis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchiectasis drugs market

Detailed Segmentation:

  • Bronchiectasis drugs market, By Drug Class:
    • Antibiotics
    • Mucolytics
    • Bronchodilators
    • Anti-inflammatory agents
  • Bronchiectasis drugs market, By Route of Administration:
    • Oral
    • Inhalation
    • Intravenous
  • Bronchiectasis drugs market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Bronchiectasis drugs market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles:
    • Bayer AG
    • GlaxoSmithKline
    • Boehringer Ingelheim
    • Novartis
    • AstraZeneca
    • Sunovion Pharmaceuticals
    • Chiesi Farmaceutici

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Bronchiectasis Drugs, By Drug Class
    • Market Bronchiectasis Drugs, By Route of Administration
    • Market Bronchiectasis Drugs, By Distribution Channel
    • Market Bronchiectasis Drugs, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing Prevalence of Bronchiectasis
  • Increasing Awareness of the Disease
    • Restraints
  • Limited Awareness and Underdiagnoses
  • Lack of Specific Treatment Guidelines
    • Opportunities
  • Unmet Medical Needs
  • Emerging Markets
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Bronchiectasis Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Bronchiectasis Drugs Market, By Drug Class, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Antibiotics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Mucolytics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Bronchodilators
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Anti-inflammatory agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Bronchiectasis Drugs Market, By Route of Administration, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Million)
  • Inhalation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Million)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Million)

7. Bronchiectasis Drugs Market, By Distribution Channel, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Million)

8. Bronchiectasis Drugs Market, By Region, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Country, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Country 2021 -2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032,(US$ Mn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032,(US$ Mn)
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032,(US$ Mn)
      • China
      • Japan
      • India
      • South Korea
      • ASEAN
      • Australia
      • Rest of Middle East
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032,(US$ Mn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032,(US$ Mn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032,(US$ Mn)
      • South Africa
      • North Africa
      • Central Africa

9. Competitive Landscape

  • Bayer
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Novartis
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sunovion Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Chiesi Farmaceutici
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

10. Section

  • Research Methodology
  • About us